Contemporary Incidence and Predictors of Major Adverse Cardiac Events After Saphenous Vein Graft Intervention With Embolic Protection (an AMEthyst Trial Substudy)

American Journal of Cardiology

Volumn 105, Issue 8, 2010, Pages 1060-1064

  Naidu, Srihari S ^a   Turco, Mark A ^b   Mauri, Laura ^c   Coolong, Alanna ^d   Popma, Jeffrey J ^e   Kereiakes, Dean J ^f  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b WASHINGTON ADVENTIST HOSPITAL   (United States)

^c HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN RECEPTOR ANTAGONIST;

ADVERSE OUTCOME; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DEVICE; DISEASE SEVERITY; DRUG ELUTING STENT; EMBOLIC PROTECTION DEVICE; EMBOLISM; EMBOLISM PREVENTION; FEMALE; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SAPHENOUS VEIN GRAFT; VEIN GRAFT;

AGED; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; DRUG-ELUTING STENTS; EMBOLISM; FEMALE; HUMANS; INCIDENCE; MALE; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RISK FACTORS; SAPHENOUS VEIN; SURVIVAL RATE; TICLOPIDINE; UNITED STATES;

EID: 77950368191     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.12.004     Document Type: Article

References (14)

1. Coolong A., Baim D.S., Kuntz R.E., O'Malley A.J., Marulkar S., Cutlip D.E., Popma J.J., and Mauri L. Saphenous vein graft stenting and major adverse cardiac events: A predictive model derived from a pooled analysis of 3958 patients. Circulation 117 (2008) 790-797
2. Topol E.J., and Yadav J.S. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 101 (2000) 570-580
3. Piana R.N., Paik G.Y., Moscucci M., Cohen D.J., Gibson C.M., Kugelmass A.D., Carrozza Jr. J.P., Kuntz R.E., and Baim D.S. Incidence and treatment of "no-reflow" after percutaneous coronary intervention. Circulation 89 (1994) 2514-2518
4. Webb J.G., Carere R.G., Virmani R., Baim D., Teirstein P.S., Whitlow P., McQueen C., Kolodgie F.D., Buller E., Dodek A., Mancini G.B., and Oesterle S. Retrieval and analysis of particulate debris after saphenous vein graft intervention. J Am Coll Cardiol 34 (1999) 468-475
5. Grube E., Gerckens U., Yeung A.C., Rowold S., Kirchhof N., Sedgewick J., Yadav J.S., and Stertzer S. Prevention of distal embolization during coronary angioplasty in saphenous vein grafts and native vessels using porous filter protection. Circulation 104 (2001) 2436-2441
6. Gorog D.A., Foale R.A., and Malik I. Distal myocardial protection during percutaneous coronary intervention: when and where?. J Am Coll Cardiol 46 (2005) 1434-1445
7. Keeley E.C., Velez C.A., O'Neill W.W., and Safian R.D. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 38 (2001) 659-665
8. Hong M.K., Mehran R., Dangas G., Mintz G.S., Lansky A.J., Pichard A.D., Kent K.M., Satler L.F., Stone G.W., and Leon M.B. Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. Circulation 100 (1999) 2400-2405
9. Mehta S.K., Frutkin A.D., Milford-Beland S., Klein L.W., Shaw R.E., Weintraub W.S., Krone R.J., Anderson H.V., Kutcher M.A., and Marso S.P. Utilization of distal embolic protection in saphenous vein graft interventions (an analysis of 19,546 patients in the American College of Cardiology-National Cardiovascular Data Registry). Am J Cardiol 100 (2007) 1114-1118
10. Kereiakes D.J., Turco M.A., Breall J., Farhat N.Z., Feldman R.L., McLaurin B., Popma J.J., Mauri L., Zimetbaum P., Massaro J., and Cutlip D.E. A novel filter-based distal embolic protection device for percutaneous intervention of saphenous vein graft lesions: results of the AMEthyst randomized controlled trial. J Am Coll Cardiol Interv 1 (2008) 248-257
11. Lansky A., and Popma J.J. Qualitative and quantitative angiography. In: Topol E.J. (Ed). Textbook of Interventional Cardiology (1999), WB Saunders, Philadelphia 725-747
12. Giugliano G.R., Kuntz R.E., Popma J.J., Cutlip D.E., and Baim D.S. Determinants of 30-day adverse events following saphenous vein graft intervention with and without a distal occlusion embolic protection device. Am J Cardiol 95 (2005) 173-177
13. Kirtane A.J., Heyman E.R., Metzger C., Breall J.A., and Carrozza Jr. J.P. Correlates of adverse events during saphenous vein graft intervention with distal embolic protection: a PRIDE stubstudy. J Am Coll Cardiol Interv 1 (2008) 186-191
14. Mauri L., Cox D., Hermiller J., Massaro J., Wahr J., Tay S.W., Jonas M., Popma J.J., Pavliska J., Wahr D., and Rogers C. The PROXIMAL trial: proximal protection during saphenous vein graft intervention using the Proxis embolic protection system: a randomized prospective multicenter clinical trial. J Am Coll Cardiol 50 (2007) 1442-1449